Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Sorrento Therapeutics, Inc. (SRNE : NSDQ)
 
 • Company Description   
Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is focused primarily on the acquisition, discovery, development and commercialization of proprietary oncology therapeutics. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic disease and infectious disease. Sorrento Therapeutics, Inc. is based in San Diego, California.

Number of Employees: 799

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.58 Daily Weekly Monthly
20 Day Moving Average: 10,216,579 shares
Shares Outstanding: 388.95 (millions)
Market Capitalization: $614.53 (millions)
Beta: 2.43
52 Week High: $11.07
52 Week Low: $1.15
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -7.06% 4.68%
12 Week -39.46% -33.44%
Year To Date -66.02% -58.48%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
4955 DIRECTORS PLACE
-
SAN DIEGO,CA 92121
USA		 ph: 858-203-4100
fax: 858-210-3759		 investors@sorrentotherapeutics.com http://www.sorrentotherapeutics.com
 
 • General Corporate Information   
Officers
Henry Ji - Chairman; Chief Executive Officer and President
Dorman Followwill - Director
Yue Alexander Wu - Director
Kim D. Janda - Director
Jaisim Shah - Director

Peer Information
Sorrento Therapeutics, Inc. (CORR.)
Sorrento Therapeutics, Inc. (RSPI)
Sorrento Therapeutics, Inc. (CGXP)
Sorrento Therapeutics, Inc. (BGEN)
Sorrento Therapeutics, Inc. (GTBP)
Sorrento Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 83587F202
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 05/25/22
Share - Related Items
Shares Outstanding: 388.95
Most Recent Split Date: (:1)
Beta: 2.43
Market Capitalization: $614.53 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.81 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/25/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.72
Price/Cash Flow: -
Price / Sales: 10.77
EPS Growth
vs. Year Ago Period: -21.21%
vs. Previous Quarter: -21.21%
Sales Growth
vs. Year Ago Period: 28.97%
vs. Previous Quarter: 40.60%
ROE
03/31/22 - -259.47
12/31/21 - -230.01
09/30/21 - -166.48
ROA
03/31/22 - -52.29
12/31/21 - -50.69
09/30/21 - -42.75
Current Ratio
03/31/22 - 1.62
12/31/21 - 1.24
09/30/21 - 1.15
Quick Ratio
03/31/22 - -
12/31/21 - 1.18
09/30/21 - 1.11
Operating Margin
03/31/22 - -706.51
12/31/21 - -680.28
09/30/21 - -558.20
Net Margin
03/31/22 - -826.96
12/31/21 - -809.63
09/30/21 - -692.36
Pre-Tax Margin
03/31/22 - -883.87
12/31/21 - -874.28
09/30/21 - -687.11
Book Value
03/31/22 - 0.58
12/31/21 - 0.26
09/30/21 - 0.43
Inventory Turnover
03/31/22 - 2.03
12/31/21 - 2.90
09/30/21 - 4.26
Debt-to-Equity
03/31/22 - 0.42
12/31/21 - 1.42
09/30/21 - 0.64
Debt-to-Capital
03/31/22 - 29.81
12/31/21 - 58.61
09/30/21 - 38.87
 

Powered by Zacks Investment Research ©